Korsana Biosciences (KRSA) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
- Closed at $33.65, -1.95% vs the prior close of $34.32.
- Volume 176.00K shares, 3.6x its 50-day average (heavy).
- New SEC filings: SCHEDULE 13G/A (Oct 15, 2026), DEF 14A (Oct 15, 2026).
- No new insider buys or sales reported since the prior session.
KRSA dips 2.0% to $33.65 on 3.6x normal volume. Closed at $33.65, -1.95% vs the prior close of $34.32. Day range $33.42–$35.15, opened at $34.70.
KRSA daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — KRSA dips 2.0% to $33.65 on 3.6x normal volume
- Closed at $33.65, -1.95% vs the prior close of $34.32. Day range $33.42–$35.15, opened at $34.70.
- Volume was 176.00K shares, 3.6x its 50-day average of 49.52K — unusually heavy trading.
- Price is +11.8% vs its 50-day average ($30.11) and +61.5% vs its 200-day average ($20.83).
- 52-week range $7.19–$59.36; today's close sits at 51% of that range, 43.3% below the 52-week high.
- SEC filings that day: DEF 14A.
Oct 14, 2026 — KRSA jumps 8.4% to $34.32 on 4.2x normal volume
- Closed at $34.32, +8.40% vs the prior close of $31.66. Day range $30.77–$34.50, opened at $32.11.
- Volume was 193.60K shares, 4.2x its 50-day average of 45.67K — unusually heavy trading.
- Price is +14.7% vs its 50-day average ($29.93) and +65.8% vs its 200-day average ($20.70).
- 52-week range $7.19–$59.36; today's close sits at 52% of that range, 42.2% below the 52-week high.
Oct 13, 2026 — KRSA slides 7.0% to $31.66 on 4.0x normal volume
- Closed at $31.66, -6.99% vs the prior close of $34.04. Day range $31.00–$35.19, opened at $35.19.
- Volume was 170.60K shares, 4.0x its 50-day average of 42.27K — unusually heavy trading.
- Price is +6.5% vs its 50-day average ($29.74) and +53.8% vs its 200-day average ($20.58).
- 52-week range $7.19–$59.36; today's close sits at 47% of that range, 46.7% below the 52-week high.
Oct 12, 2026 — KRSA rises 0.4% to $34.04, 3 up days in a row
- Closed at $34.04, +0.35% vs the prior close of $33.92. Day range $33.10–$35.17, opened at $34.25.
- Volume was 59.20K shares, 1.4x its 50-day average of 41.13K.
- Price is +15.0% vs its 50-day average ($29.59) and +66.3% vs its 200-day average ($20.47).
- 52-week range $7.19–$59.36; today's close sits at 51% of that range, 42.7% below the 52-week high.
- That makes 3 straight gains.
Oct 9, 2026 — KRSA rises 1.2% to $33.92
- Closed at $33.92, +1.22% vs the prior close of $33.51. Day range $33.33–$35.34, opened at $33.50.
- Volume was 45.90K shares, 1.1x its 50-day average of 40.22K.
- Price is +15.4% vs its 50-day average ($29.39) and +66.7% vs its 200-day average ($20.35).
- 52-week range $7.19–$59.36; today's close sits at 51% of that range, 42.9% below the 52-week high.
Oct 8, 2026 — KRSA jumps 5.9% to $33.51 on 5.3x normal volume
- Closed at $33.51, +5.88% vs the prior close of $31.65. Day range $31.45–$33.90, opened at $31.65.
- Volume was 194.10K shares, 5.3x its 50-day average of 36.37K — unusually heavy trading.
- Price is +14.7% vs its 50-day average ($29.20) and +65.6% vs its 200-day average ($20.23).
- 52-week range $7.19–$59.36; today's close sits at 50% of that range, 43.5% below the 52-week high.
Oct 7, 2026 — KRSA dips 0.4% to $31.65
- Closed at $31.65, -0.38% vs the prior close of $31.77. Day range $31.00–$32.40, opened at $32.36.
- Volume was 37.10K shares, 1.0x its 50-day average of 35.68K.
- Price is +9.1% vs its 50-day average ($29.02) and +57.3% vs its 200-day average ($20.12).
- 52-week range $7.19–$59.36; today's close sits at 47% of that range, 46.7% below the 52-week high.
Oct 6, 2026 — KRSA jumps 3.4% to $31.77
- Closed at $31.77, +3.42% vs the prior close of $30.72. Day range $30.50–$31.92, opened at $30.50.
- Volume was 42.00K shares, 1.2x its 50-day average of 34.88K.
- Price is +10.0% vs its 50-day average ($28.88) and +58.8% vs its 200-day average ($20.01).
- 52-week range $7.19–$59.36; today's close sits at 47% of that range, 46.5% below the 52-week high.
Oct 5, 2026 — KRSA rises 0.8% to $30.72 on 3.2x normal volume
- Closed at $30.72, +0.75% vs the prior close of $30.49. Day range $29.93–$31.66, opened at $30.49.
- Volume was 104.30K shares, 3.2x its 50-day average of 33.01K — unusually heavy trading.
- Price is +6.9% vs its 50-day average ($28.73) and +54.4% vs its 200-day average ($19.90).
- 52-week range $7.19–$59.36; today's close sits at 45% of that range, 48.2% below the 52-week high.
Oct 2, 2026 — KRSA dips 2.3% to $30.49, 3 down days in a row
- Closed at $30.49, -2.28% vs the prior close of $31.20. Day range $29.50–$32.64, opened at $31.79.
- Volume was 51.70K shares, 1.6x its 50-day average of 31.99K.
- Price is +6.6% vs its 50-day average ($28.61) and +54.0% vs its 200-day average ($19.80).
- 52-week range $7.19–$59.36; today's close sits at 45% of that range, 48.6% below the 52-week high.
- That makes 3 straight losses.
KRSA latest news & SEC filings
Every SEC filing by or about KRSA in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 15, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 5, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Sep 23, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 22, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 18, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 18, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 16, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 15, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 11, 2026 · Form SCHEDULE 13D — Activist-style stake (13D)
Activist-style stake (13D) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Sep 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.01 — Completed an acquisition or sale of assets.
- Item 2.02 — Reported results of operations (earnings release).
- Item 3.02 — Sold unregistered shares.
- Item 3.03 — Change to shareholder rights.
- Item 5.01 — Change in control of the company.
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.03 — Amended its charter or bylaws / changed fiscal year.
- Item 5.05 — Changed or waived its code of ethics.
- Item 5.06
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 10, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade KRSA
- Last results release: Sep 11, 2026 (8-K Item 2.02). Previous ones: May 12, 2023, Mar 22, 2023, Aug 9, 2022. Based on that rhythm, the next report is likely around Dec 11, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 5.22% (largest 16.6%). That is a volatile stock.
- Liquidity: about 97.66K shares (≈$3.29M) trade per day on average.
- 52-week position: $33.65 vs a range of $7.19–$59.36 (51% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: 1:7 on Sep 9, 2026
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Sep 11, 2026; 8-K Aug 27, 2026; 8-K Aug 25, 2026.
- Share count: 4.68M shares outstanding (Aug 4, 2026), +40.3% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
KRSA market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 34.70 | 35.15 | 33.42 | 33.65 | 176.00K |
| Oct 14, 2026 | 32.11 | 34.50 | 30.77 | 34.32 | 193.60K |
| Oct 13, 2026 | 35.19 | 35.19 | 31.00 | 31.66 | 170.60K |
| Oct 12, 2026 | 34.25 | 35.17 | 33.10 | 34.04 | 59.20K |
| Oct 9, 2026 | 33.50 | 35.34 | 33.33 | 33.92 | 45.90K |
| Oct 8, 2026 | 31.65 | 33.90 | 31.45 | 33.51 | 194.10K |
| Oct 7, 2026 | 32.36 | 32.40 | 31.00 | 31.65 | 37.10K |
| Oct 6, 2026 | 30.50 | 31.92 | 30.50 | 31.77 | 42.00K |
| Oct 5, 2026 | 30.49 | 31.66 | 29.93 | 30.72 | 104.30K |
| Oct 2, 2026 | 31.79 | 32.64 | 29.50 | 30.49 | 51.70K |
| Oct 1, 2026 | 31.43 | 32.03 | 30.75 | 31.20 | 14.70K |
| Sep 30, 2026 | 34.30 | 34.33 | 30.25 | 32.00 | 121.10K |
| Sep 29, 2026 | 32.40 | 36.77 | 30.94 | 34.00 | 96.90K |
| Sep 28, 2026 | 32.50 | 33.75 | 29.03 | 30.83 | 51.50K |
| Sep 25, 2026 | 37.19 | 37.25 | 30.59 | 31.00 | 34.80K |
| Sep 24, 2026 | 31.72 | 37.26 | 31.65 | 37.19 | 411.30K |
| Sep 23, 2026 | 34.97 | 35.39 | 31.25 | 32.30 | 66.30K |
| Sep 22, 2026 | 34.37 | 34.99 | 30.80 | 34.98 | 26.60K |
| Sep 21, 2026 | 33.45 | 34.40 | 31.90 | 33.21 | 21.70K |
| Sep 18, 2026 | 33.32 | 35.47 | 32.00 | 34.99 | 33.70K |
About Korsana Biosciences
Korsana Biosciences (KRSA) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in WALTHAM, MA. State of incorporation: MA. Fiscal year ends December 31. SEC CIK 1755237.
KRSA board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Funds Management Llc Fairmount | Director | Sep 10, 2026 |
| Healthcare Co-Invest Vi L.P. Fairmount | Director | Sep 10, 2026 |
| Healthcare Fund Ii L.P. Fairmount | Director | Sep 10, 2026 |
| Andrew Gottesdiener | Director | Sep 10, 2026 |
| Regina Margaret Graul | See Remarks | Aug 18, 2026 |
| Heidi Henson | Director | Sep 10, 2026 |
| Peter Evan Harwin | Director | Sep 10, 2026 |
| Peter M Hecht | Director | Jul 20, 2026 |
| Tomas Kiselak | Director | Sep 10, 2026 |
| Michelle Patricia Pernice | Director | Sep 10, 2026 |
| Nimish P Shah | Director | Sep 10, 2026 |
| Jonathan Violin | See Remarks | Sep 10, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Rhonda M. Chicko | Chief Financial Officer | Aug 18, 2026 |
| Regina Margaret Graul | See Remarks | Aug 18, 2026 |
| Matthew James Leoni | Chief Medical Officer | Sep 10, 2026 |
| Mark J. Vignola | Chief Financial Officer | Sep 10, 2026 |
| Jonathan Violin | See Remarks | Sep 10, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
KRSA financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | — | $-3.53M | -1.11 | $-3.31M |
| Dec 31, 2024 | — | $-3.06M | -1.21 | $-4.33M |
| Dec 31, 2023 | — | $-5.26M | -2.25 | $-21.25M |
| Dec 31, 2022 | — | $-44.08M | -20.28 | $-40.61M |
| Dec 31, 2021 | — | $-51.65M | -1.32 | $-36.52M |
Latest balance sheet: total assets $6.93M, total liabilities $—, cash $1.39M (as of Jun 30, 2026).
KRSA earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Sep 11, 2026 | 8-K Item 2.02 (results) | $31.91 |
| May 12, 2023 | 8-K Item 2.02 (results) | — |
| Mar 22, 2023 | 8-K Item 2.02 (results) | — |
| Aug 9, 2022 | 8-K Item 2.02 (results) | — |
| May 4, 2022 | 8-K Item 2.02 (results) | — |
| Feb 24, 2022 | 8-K Item 2.02 (results) | — |
| Nov 9, 2021 | 8-K Item 2.02 (results) | — |
| Jul 29, 2021 | 8-K Item 2.02 (results) | — |
| Apr 27, 2021 | 8-K Item 2.02 (results) | — |
| Jan 13, 2021 | 8-K Item 2.02 (results) | — |
| Aug 3, 2020 | 8-K Item 2.02 (results) | — |
| Jul 9, 2020 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Regeneron Pharmaceuticals (REGN)Novo Nordisk A S (NVO)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)Space Exploration Technologies (SPCX)AMD (AMD)Apple (AAPL)Tesla (TSLA)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on KRSA
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.